WSTAM
SRPT icon

Wilbanks Smith & Thomas Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-200
Closed -$32K – 1179
2018
Q3 		$32K Buy
+200
New +$27.3K ﹤0.01% 779

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's SRPT Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Sarepta Therapeutics (SRPT) in Q4 2018, closing a stake of 200 shares — an estimated $32K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in SRPT in Q3 2018 and held it in 1 quarter. The position peaked at $32K in Q3 2018. 336 funds tracked by Wall St. Rank hold SRPT as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Sarepta Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 200 Sarepta Therapeutics shares in Q4 2018, an estimated $32K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Sarepta Therapeutics position peaked at $32K in Q3 2018.
  • 336 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.